1 REPORT PROLOGUE
2 INTRODUCTION
2.1 DEFINITION
2.1.1 DEFINITION OF FACIAL INJECTABLES
2.1.2 SPECIFICATIONS OF FACIAL INJECTABLES
2.1.3 CLASSIFICATION OF FACIAL INJECTABLES
2.1.4 MARKET SEGMENT BY REGIONS
2.2 SCOPE OF THE STUDY
2.2.1 RESEARCH OBJECTIVE
2.2.2 ASSUMPTIONS
2.2.3 LIMITATIONS
2.3 MARKET STRUCTURE
2.4. MARKET SEGMENTATION
3 RESEARCH METHODOLOGY
3.1 RESEARCH PROCESS
3.2 PRIMARY RESEARCH
3.3 SECONDARY RESEARCH
3.4 MARKET SIZE ESTIMATION
3.5 FORECAST MODEL
4 MARKET DYNAMICS
4.1 DRIVERS
4.2 RESTRAINTS
4.3 OPPORTUNITIES
5 EUROPE FACIAL INJECTABLESMARKET: BY TYPES (USD MILLION)
6.1 INTRODUCTION
6.2 HISTORIC MARKET GROWTH
6.3 MARKET SIZE (SUB SEGMENTS)
6.3.1 BOTULINUM TOXIN
6.3.2 HYALURONIC ACID
6.3.3 COLLAGEN
6.3.4 POLYMERS AND PARTICLES (PPFS)
6 EUROPE FACIAL INJECTABLESMARKET, BY REGION (USD MILLION)
6.1 INTRODUCTION
6.2 NORTH AMERICA
6.2.1 US
6.2.2 CANADA
6.3 EUROPE
6.3.1 WESTERN EUROPE
6.3.1.1 GERMANY
6.3.1.2 FRANCE
6.3.1.3 ITALY
6.3.1.4 SPAIN
6.3.1.5 UK
6.3.1.6 REST OF WESTERN EUROPE
6.3.2 EASTERN EUROPE
6.4 ASIA-PACIFIC
6.4.1 CHINA
6.4.2 INDIA
6.4.3 JAPAN
6.4.4 SOUTH EAST ASIA
7 EUROPE FACIAL INJECTABLESMARKET: COMPANY LANDSCAPE
7.1 INTRODUCTION
7.2 COMPANY SHARE ANALYSIS (%)
7.3 COMPETITIVE LANDSCAPE
7.3.1 PRODUCT LAUNCH/DEVELOPMENT
7.3.2 PARTNERSHIPS AND COLLABORATIONS
7.3.3 ACQUISITIONS
7.3.4 BUSINESS EXPANSION
8 COMPANY PROFILE
8.1 ALLERGAN
8.1.1 COMPANY OVERVIEW
8.1.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.1.3 FINANCIAL UPDATES
8.1.4 KEY DEVELOPMENTS
8.2 LUMINERA DERM LTD
8.2.1 COMPANY OVERVIEW
8.2.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.2.3 FINANCIAL UPDATES
8.2.4 KEY DEVELOPMENTS
8.3 MERZ PHARMA
8.3.1 COMPANY OVERVIEW
8.3.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.3.3 FINANCIAL UPDATES
8.3.4 KEY DEVELOPMENTS
8.4 IPSEN
8.4.1 COMPANY OVERVIEW
8.4.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.4.3 FINANCIAL UPDATES
8.4.4 KEY DEVELOPMENTS
8.5 ETHICON
8.5.1 COMPANY OVERVIEW
8.5.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.5.3 FINANCIAL UPDATES
8.5.4 KEY DEVELOPMENTS
8.6 VALEANT PHARMACEUTICALS INTERNATIONAL
8.6.1 COMPANY OVERVIEW
8.6.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.6.3 FINANCIAL UPDATES
8.6.4 KEY DEVELOPMENTS
8.7 GALDERMA
8.7.1 COMPANY OVERVIEW
8.7.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.7.3 FINANCIAL UPDATES
8.7.4 KEY DEVELOPMENTS
8.8 FIBROGEN
8.8.1 COMPANY OVERVIEW
8.8.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.8.3 FINANCIAL UPDATES
8.8.4 KEY DEVELOPMENTS
8.9 TEI BIOSCIENCES
8.9.1 COMPANY OVERVIEW
8.9.2 PRODUCT/BUSINESS SEGMENT OVERVIEW
8.9.3 FINANCIAL UPDATES
8.9.4 KEY DEVELOPMENTS
9 APPENDIX